Reuters logo
BRIEF-Onxeo announces top-line results from ReLive Phase III study of Livatag in advanced hepatocellular carcinoma
September 11, 2017 / 6:11 PM / in a month

BRIEF-Onxeo announces top-line results from ReLive Phase III study of Livatag in advanced hepatocellular carcinoma

Sept 11 (Reuters) - Onxeo Sa -

* Onxeo announces top-line results from ReLive Phase III study of Livatag® in advanced hepatocellular carcinoma

* Study did not meet its primary endpoint of improving survival over the comparative group

* Monitoring of patients still enrolled in study will continue to completion expected in h1 2019 Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below